Table 1.
Base‐Case Model Results
| Commercial | Medicare Advantage | |||||
|---|---|---|---|---|---|---|
| Ivabradine | Background Therapy | Incremental | Ivabradine | Background Therapy | Incremental | |
| Hospitalization costs | ||||||
| HF | $254 960 | $286 255 | −$31 295 | $143 394 | $159 515 | −$16 121 |
| Cardiovascular | $287 802 | $321 915 | −$34 112 | $165 010 | $182 681 | −$17 672 |
| All cause | $337 268 | $375 634 | −$38 366 | $200 032 | $220 887 | −$20 855 |
| AE costs | $5294 | $2722 | $2571 | $2581 | $1325 | $1256 |
| Drug costs | $27 201 | NA | $27 201 | $24 512 | NA | $24 512 |
| Total costs | $369 762 | $378 356 | −$8594 | $227 125 | $222 212 | $4913 |
| Health outcomes | ||||||
| LYs | 6.04 | 5.83 | 0.21 | 5.45 | 5.28 | 0.16 |
| QALYs | 4.02 | 3.78 | 0.24 | 3.60 | 3.40 | 0.20 |
AE indicates adverse event; HF, heart failure; LYs, life years; NA, not applicable; QALY, quality‐adjusted life year.